ALHC

SEC source: 0001209191-22-017942 · doc4.xml · nonDerivative · entry 1

HODGSON DAVID C · CIK 0001193346 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,379

F1 · kind: Represents 16,556 restricted stock units, each restricted stock unit representing a right to receive one share of Common Stock of the Company, all of which will vest on the one-year anniversary of the grant date unless the reporting person ceases to serve as a member of the Board of Directors prior to such date. The reporting person has elected to defer receipt of the underlying shares until separation of service as a director (or, if earlier, upon a change of control of the Company).

SEC source: 0001209191-22-017994 · doc4.xml · nonDerivative · entry 1

McClellan Mark B. · CIK 0001567006 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 293,375

F1 · kind: Represents 16,556 restricted stock units, each restricted stock unit representing a right to receive one share of Common Stock of the Company, all of which will vest on the one-year anniversary of the grant date unless the reporting person ceases to serve as a member of the Board of Directors prior to such date.

SEC source: 0001209191-22-017999 · doc4.xml · nonDerivative · entry 1

Vorhoff Nicholas Robbert · CIK 0001794455 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,379

F1 · kind: Represents 16,556 restricted stock units, each restricted stock unit representing a right to receive one share of Common Stock of the Company, all of which will vest on the one-year anniversary of the grant date unless the reporting person ceases to serve as a member of the Board of Directors prior to such date. The reporting person has elected to defer receipt of the underlying shares until separation of service as a director (or, if earlier, until a change of control of the Company).

SEC source: 0001209191-22-000361 · doc4.xml · nonDerivative · entry 1

BILNEY JODY L · CIK 0001185995 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,674

F1 · kind: Represents 28,674 restricted stock units, each restricted stock unit representing a right to receive one share of Common Stock of the Company, that will vest in equal installments on each of the first three anniversaries of the grant date unless the reporting person ceases to serve as a member of the Board of Directors prior to the applicable vesting dates.

SEC source: 0001209191-22-000363 · doc4.xml · nonDerivative · entry 1

JORDEN YON · CIK 0001189397 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,674

F1 · kind: Represents 28,674 restricted stock units, each restricted stock unit representing a right to receive one share of Common Stock of the Company, that will vest in equal installments on each of the first three anniversaries of the grant date unless the reporting person ceases to serve as a member of the Board of Directors prior to the applicable vesting dates.

SEC source: 0000950142-21-003819 · es210205315_4-alhcwp2.xml · nonDerivative · entry 1

Warburg Pincus Partners GP LLC · CIK 0001621224 · Director · 10% owner

WARBURG PINCUS & CO. · CIK 0000929408 · Director · 10% owner

Warburg Pincus Partners II Holdings, L.P. · CIK 0001894855 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 22,768,785

F1 · kind: Represents 1,310,079 shares of Common Stock sold by Warburg Pincus Private Equity XII, L.P., a Delaware limited partnership ("WP XII"), 262,845 shares of Common Stock sold by Warburg Pincus Private Equity XII-B, L.P., a Delaware limited partnership ("WP XII-B"), 37,811 shares of Common Stock sold by Warburg Pincus Private Equity XII-D, L.P., a Delaware limited partnership ("WP XII-D"), and 215,801 shares of Common Stock sold by Warburg Pincus Private Equity XII-E, L.P., a Delaware limited partnership ("WP XII-E"), 70,679 shares of Common Stock sold by WP XII Partners, L.P., a Delaware limited partnership ("WP XII Partners"), 136,721 shares of Common Stock sold by Warburg Pincus XII Partners, L.P., a Delaware limited partnership ("Warburg Pincus XII Partners") pursuant to a registered public offering that closed on November 23, 2021 (the "Transaction"), at a price of $20.1075 (net of underwriting discount).

F2 · ownership.nature: Reflects securities held directly by WP XII, WP XII-B, WP XII-D, WP XII-E, WP XII Partners, and Warburg Pincus XII Partners (together with WP XII, WP XII-B, WP XII-D, WP XII-E, and WP XII Partners, the "WP XII Funds") following the closing of the Transaction. Warburg Pincus XII, L.P., a Delaware limited partnership ("WP XII GP"), is the general partner of the WP XII Funds. WP Global LLC, a Delaware limited liability company ("WP Global"), is the general partner of WP XII GP. Warburg Pincus Partners II, L.P., a Delaware limited partnership ("WPP II"), is the managing member of WP Global. Warburg Pincus Partners II Holdings, L.P., a Delaware limited partnership ("WPP II Holdings"), is a limited partner of WPP II. Warburg Pincus Partners GP LLC, a Delaware limited liability company ("WPP GP"), is the general partner of WPP II and WPP II Holdings. Warburg Pincus & Co., a New York general partnership ("WP"), is the managing member of WPP GP. (Cont'd in FN3)

F3 · ownership.nature: (Cont'd from FN2) Warburg Pincus LLC, a New York limited liability company ("WP LLC") is a registered investment adviser and the manager of the WP XII Funds. Investment and voting decisions with respect to the shares held by the WP XII Funds are made by a committee comprised of three or more individuals and all members of such committee disclaim beneficial ownership of the shares.

SEC source: 0000950142-21-003820 · es210205313_4-alhc1.xml · nonDerivative · entry 1

GENERAL ATLANTIC, L.P. · CIK 0001017645 · Director · 10% owner

GENERAL ATLANTIC GENPAR, L.P. · CIK 0001467926 · Director · 10% owner

General Atlantic Partners 95, L.P. · CIK 0001606259 · Director · 10% owner

GAP COINVESTMENTS III, LLC · CIK 0001282203 · Director · 10% owner

GAP COINVESTMENTS IV, LLC · CIK 0001282372 · Director · 10% owner

GAP Coinvestments V, LLC · CIK 0001793941 · Director · 10% owner

GAPCO GMBH & CO KG · CIK 0001187388 · Director · 10% owner

GAPCO MANAGEMENT GMBH · CIK 0001187390 · Director · 10% owner

GAP Coinvestments CDA, L.P. · CIK 0001356474 · Director · 10% owner

General Atlantic (SPV) GP, LLC · CIK 0001793940 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 70,069,317

F1 · kind: The shares of Common Stock were sold by General Atlantic (ALN HLTH), L.P., a Delaware limited partnership ("GA ALN"), pursuant to a registered public offering that closed on November 23, 2021 (the "Transaction"), at a price of $20.1075 (net of underwriting discount).

F2 · ownership.nature: Reflects securities held directly by GA ALN following the closing of the Transaction. The limited partners of GA ALN are the following investment funds (the "GA Funds"): General Atlantic Partners 95, L.P., a Delaware limited partnership ("GAP 95"), GAP Coinvestments CDA, L.P., a Delaware limited partnership ("GAPCO CDA"), GAP Coinvestments III, LLC, a Delaware limited liability company ("GAPCO III"), GAP Coinvestments IV, LLC, a Delaware limited liability company ("GAPCO IV"), GAP Coinvestments V, LLC, a Delaware limited liability company ("GAPCO V") and GAPCO GmbH & Co. KG, a German partnership ("GAPCO KG"). (Cont'd in FN3)

F3 · ownership.nature: (Cont'd from FN2) General Atlantic GenPar, L.P., a Delaware limited partnership ("GA GenPar"), is the general partner of GAP 95. General Atlantic (SPV) GP, LLC, a Delaware limited liability company ("GA SPV"), is the general partner of GA ALN. General Atlantic, L.P., a Delaware limited partnership ("GA LP") is the general partner of GA GenPar and GAPCO CDA, the managing member of GAPCO III, GAPCO IV and GAPCO V, and the sole member of GA SPV. GA LP is controlled by the Management Committee of GASC MGP, LLC (the "Management Committee"). GAPCO Management GmbH, a German company ("GAPCO Management"), is the general partner of GAPCO KG. There are nine members of the Management Committee. Each of the members of the GA Management Committee disclaims ownership of the shares except to the extent he has a pecuniary interest therein.

SEC source: 0000950142-21-003818 · es210205314_4-alhcwp1.xml · nonDerivative · entry 1

WARBURG PINCUS LLC · CIK 0001162870 · Director · 10% owner

Warburg Pincus Private Equity XII, L.P. · CIK 0001658396 · Director · 10% owner

Warburg Pincus Private Equity XII-B, L.P. · CIK 0001658398 · Director · 10% owner

Warburg Pincus Private Equity XII-D, L.P. · CIK 0001658400 · Director · 10% owner

Warburg Pincus Private Equity XII-E, L.P. · CIK 0001658404 · Director · 10% owner

WP XII Partners, L.P. · CIK 0001658414 · Director · 10% owner

Warburg Pincus XII Partners, L.P. · CIK 0001658412 · Director · 10% owner

WARBURG PINCUS XII, L.P. · CIK 0001672765 · Director · 10% owner

WP Global LLC · CIK 0001540385 · Director · 10% owner

Warburg Pincus Partners II, L.P. · CIK 0001658787 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 22,768,785

F1 · kind: Represents 1,310,079 shares of Common Stock sold by Warburg Pincus Private Equity XII, L.P., a Delaware limited partnership ("WP XII"), 262,845 shares of Common Stock sold by Warburg Pincus Private Equity XII-B, L.P., a Delaware limited partnership ("WP XII-B"), 37,811 shares of Common Stock sold by Warburg Pincus Private Equity XII-D, L.P., a Delaware limited partnership ("WP XII-D"), and 215,801 shares of Common Stock sold by Warburg Pincus Private Equity XII-E, L.P., a Delaware limited partnership ("WP XII-E"), 70,679 shares of Common Stock sold by WP XII Partners, L.P., a Delaware limited partnership ("WP XII Partners"), 136,721 shares of Common Stock sold by Warburg Pincus XII Partners, L.P., a Delaware limited partnership ("Warburg Pincus XII Partners") pursuant to a registered public offering that closed on November 23, 2021 (the "Transaction"), at a price of $20.1075 (net of underwriting discount).

F2 · ownership.nature: Reflects securities held directly by WP XII, WP XII-B, WP XII-D, WP XII-E, WP XII Partners, and Warburg Pincus XII Partners (together with WP XII, WP XII-B, WP XII-D, WP XII-E, and WP XII Partners, the "WP XII Funds") following the closing of the Transaction. Warburg Pincus XII, L.P., a Delaware limited partnership ("WP XII GP"), is the general partner of the WP XII Funds. WP Global LLC, a Delaware limited liability company ("WP Global"), is the general partner of WP XII GP. Warburg Pincus Partners II, L.P., a Delaware limited partnership ("WPP II"), is the managing member of WP Global. Warburg Pincus Partners II Holdings, L.P., a Delaware limited partnership ("WPP II Holdings"), is a limited partner of WPP II. Warburg Pincus Partners GP LLC, a Delaware limited liability company ("WPP GP"), is the general partner of WPP II and WPP II Holdings. Warburg Pincus & Co., a New York general partnership ("WP"), is the managing member of WPP GP. (Cont'd in FN3)

F3 · ownership.nature: (Cont'd from FN2) Warburg Pincus LLC, a New York limited liability company ("WP LLC") is a registered investment adviser and the manager of the WP XII Funds. Investment and voting decisions with respect to the shares held by the WP XII Funds are made by a committee comprised of three or more individuals and all members of such committee disclaim beneficial ownership of the shares.

SEC source: 0000950142-21-003821 · es210205369_4-alhc2.xml · nonDerivative · entry 1

General Atlantic (ALN HLTH), L.P. · CIK 0001853603 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 70,069,317

F1 · kind: The shares of Common Stock were sold by General Atlantic (ALN HLTH), L.P., a Delaware limited partnership ("GA ALN"), pursuant to a registered public offering that closed on November 23, 2021 (the "Transaction"), at a price of $20.1075 (net of underwriting discount).

F2 · ownership.nature: Reflects securities held directly by GA ALN following the closing of the Transaction. The limited partners of GA ALN are the following investment funds (the "GA Funds"): General Atlantic Partners 95, L.P., a Delaware limited partnership ("GAP 95"), GAP Coinvestments CDA, L.P., a Delaware limited partnership ("GAPCO CDA"), GAP Coinvestments III, LLC, a Delaware limited liability company ("GAPCO III"), GAP Coinvestments IV, LLC, a Delaware limited liability company ("GAPCO IV"), GAP Coinvestments V, LLC, a Delaware limited liability company ("GAPCO V") and GAPCO GmbH & Co. KG, a German partnership ("GAPCO KG"). (Cont'd in FN3)

F3 · ownership.nature: (Cont'd from FN2) General Atlantic GenPar, L.P., a Delaware limited partnership ("GA GenPar"), is the general partner of GAP 95. General Atlantic (SPV) GP, LLC, a Delaware limited liability company ("GA SPV"), is the general partner of GA ALN. General Atlantic, L.P., a Delaware limited partnership ("GA LP") is the general partner of GA GenPar and GAPCO CDA, the managing member of GAPCO III, GAPCO IV and GAPCO V, and the sole member of GA SPV. GA LP is controlled by the Management Committee of GASC MGP, LLC (the "Management Committee"). GAPCO Management GmbH, a German company ("GAPCO Management"), is the general partner of GAPCO KG. There are nine members of the Management Committee. Each of the members of the GA Management Committee disclaims ownership of the shares except to the extent he has a pecuniary interest therein.

SEC source: 0000950142-21-003816 · es210205306_4-maroney.xml · nonDerivative · entry 1

Maroney Dawn Christine · CIK 0001850397 · President, Markets

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,513,933

F1 · kind: Represents 127,843 shares of Common Stock sold pursuant to a registered offering which closed on November 23, 2021, at a price of $20.1075 (net of underwriting discount).

SEC source: 0000950142-21-003813 · es210205303_4-furman.xml · nonDerivative · entry 1

Furman Donald Steven · CIK 0001850417 · Chief Clinical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,829,544

F1 · kind: Represents 100,000 shares of Common Stock sold pursuant to a registered offering which closed on November 23, 2021, at a price of $20.1075 (net of underwriting discount).

SEC source: 0000950142-21-003812 · es210205301_4-freeman.xml · nonDerivative · entry 1

Freeman Robert Thomas · CIK 0001850414 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 731,939

F1 · kind: Represents 85,279 shares of Common Stock sold pursuant to a registered offering which closed on November 23, 2021, at a price of $20.1075 (net of underwriting discount).

F2 · ownership.nature: Represents securities held by FCO Holdings LLC, a limited liability company owned by FCO Holdings Trust One, an irrevocable trust of which Mr. Freeman is an indirect beneficiary.

SEC source: 0000950142-21-003815 · es210205305_4-kumar.xml · nonDerivative · entry 1

Kumar Dinesh M. · CIK 0001850439 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 987,074

F1 · kind: Represents 83,367 shares of Common Stock sold pursuant to a registered offering which closed on November 23, 2021, at a price of $20.1075 (net of underwriting discount).

SEC source: 0000950142-21-003814 · es210205304_4-kao.xml · nonDerivative · entry 1

KAO JOHN E · CIK 0001222028 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 3,565,391

F1 · kind: Represents 419,646 shares of Common Stock of Alignment Healthcare, Inc. (the "Company") sold pursuant to a registered offering which closed on November 23, 2021, at a price of $20.1075 (net of underwriting discount).

F2 · ownership.nature: Represents securities held by JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee.

SEC source: 0000950142-21-003817 · es210205309_4-mcclellan.xml · nonDerivative · entry 1

McClellan Mark B. · CIK 0001567006 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 276,819

F1 · kind: Represents 7,500 shares of Common Stock sold pursuant to a registered offering which closed on November 23, 2021, at a price of $20.1075 (net of underwriting discount).

SEC source: 0001209191-21-062729 · doc4.xml · nonDerivative · entry 2

KAO JOHN E · CIK 0001222028 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,985,037

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. The reported prices in column 4 are weighted-average prices. The Reporting Person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnotes (2) and (4) to this Form 4.

F4 · price: The shares were sold in multiple transactions at prices ranging from $19.58 to $20.45 per share.

F3 · ownership.nature: Represents securities held by JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee.

SEC source: 0001209191-21-062746 · doc4.xml · nonDerivative · entry 1

MARGOLIS JEFFREY H · CIK 0001105688 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 426,733

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F2 · ownership.nature: Represents securities held by the Margolis Family trust 12/23/98, of which Mr. Margolis is the trustee.

SEC source: 0001209191-21-062735 · doc4.xml · nonDerivative · entry 1

Kumar Dinesh M. · CIK 0001850439 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,070,441

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. The reported price in column 4 is a weighted-average price. The Reporting Person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in footnote (2) to this Form 4.

F2 · price: The shares were sold in multiple transactions at prices ranging from $19.37 to $20.13 per share.

SEC source: 0001209191-21-062729 · doc4.xml · nonDerivative · entry 1

KAO JOHN E · CIK 0001222028 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 4,014,339

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. The reported prices in column 4 are weighted-average prices. The Reporting Person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnotes (2) and (4) to this Form 4.

F2 · price: The shares were sold in multiple transactions at prices ranging from $19.37 to $20.18 per share.

F3 · ownership.nature: Represents securities held by JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee.

SEC source: 0001209191-21-061404 · doc4.xml · nonDerivative · entry 1

Freeman Robert Thomas · CIK 0001850414 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 817,218

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. The reported price in column 4 is a weighted average price. The Reporting Person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in footnote (2) to this Form 4.

F2 · price: The shares were sold in multiple transactions at prices ranging from $19.26 to $19.51 per share.

F3 · ownership.nature: Represents securities held by FCO Holdings LLC, a limited liability company owned by FCO Holdings Trust One, an irrevocable trust of which Mr. Freeman is an indirect beneficiary.

SEC source: 0000950142-21-003198 · es210192796_4-kao.xml · nonDerivative · entry 3

KAO JOHN E · CIK 0001222028 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,085,037

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. The reported prices in column 4 are weighted average prices. The Reporting Person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnotes (2), (4) and (5) to this Form 4. Transactions within a $1.00 price range are reported in accordance with the June 25, 2008 SEC No-Action letter.

F5 · price: The shares were sold in multiple transactions at prices ranging from $18.23 to $19.05 per share.

F3 · ownership.nature: Represents securities held by JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee.

SEC source: 0000950142-21-003200 · es210192798_4-margolis.xml · nonDerivative · entry 1

MARGOLIS JEFFREY H · CIK 0001105688 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 427,933

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F2 · ownership.nature: Represents securities held by the Margolis Family trust 12/23/98, of which Mr. Margolis is the trustee.

SEC source: 0000950142-21-003199 · es210192797_4-kumar.xml · nonDerivative · entry 1

Kumar Dinesh M. · CIK 0001850439 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,080,441

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. The reported prices in column 4 are weighted average prices. The Reporting Person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in footnote (2) to this Form 4.

F2 · price: The shares were sold in multiple transactions at prices ranging from $18.00 to $18.34 per share.

SEC source: 0000950142-21-003198 · es210192796_4-kao.xml · nonDerivative · entry 2

KAO JOHN E · CIK 0001222028 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,128,134

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. The reported prices in column 4 are weighted average prices. The Reporting Person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnotes (2), (4) and (5) to this Form 4. Transactions within a $1.00 price range are reported in accordance with the June 25, 2008 SEC No-Action letter.

F4 · price: The shares were sold in multiple transactions at prices ranging from $19.00 to $19.025 per share.

F3 · ownership.nature: Represents securities held by JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee.

SEC source: 0000950142-21-003198 · es210192796_4-kao.xml · nonDerivative · entry 1

KAO JOHN E · CIK 0001222028 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,129,396

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. The reported prices in column 4 are weighted average prices. The Reporting Person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnotes (2), (4) and (5) to this Form 4. Transactions within a $1.00 price range are reported in accordance with the June 25, 2008 SEC No-Action letter.

F2 · price: The shares were sold in multiple transactions at prices ranging from $18.00 to $18.97 per share.

F3 · ownership.nature: Represents securities held by JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee.

SEC source: 0000950142-21-002785 · es210181189_4-hodgson.xml · nonDerivative · entry 1

HODGSON DAVID C · CIK 0001193346 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,823

F1 · kind: Represents 32,823 restricted stock units, each restricted stock unit representing a right to receive one share of Common Stock of the Company, that will vest in equal installments on each of the first three anniversaries of the IPO unless Mr. Hodgson is removed for cause or resigns prior to such dates.

SEC source: 0000950142-21-002784 · es210181185_4-vorhoff.xml · nonDerivative · entry 1

Vorhoff Nicholas Robbert · CIK 0001794455 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,823

F1 · kind: Represents 32,823 restricted stock units, each restricted stock unit representing a right to receive one share of Common Stock of the Company, that will vest in equal installments on each of the first three anniversaries of the IPO unless Mr. Vorhoff is removed for cause or resigns prior to such dates.

SEC source: 0000899243-21-015452 · doc4.xml · nonDerivative · entry 1

WARBURG PINCUS LLC · CIK 0001162870 · Director · 10% owner

Warburg Pincus Partners GP LLC · CIK 0001621224 · Director · 10% owner

WARBURG PINCUS & CO. · CIK 0000929408 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 24,802,721

F1 · kind: Represents 461,584 shares of Common Stock sold by Warburg Pincus Private Equity XII, L.P., a Delaware limited partnership ("WP XII"), 92,610 shares of Common Stock sold by Warburg Pincus Private Equity XII-B, L.P., a Delaware limited partnership ("WP XII-B"), 13,322 shares of Common Stock sold by Warburg Pincus Private Equity XII-D, L.P., a Delaware limited partnership ("WP XII-D"), and 76,034 share of Common Stock sold by Warburg Pincus Private Equity XII-E, L.P., a Delaware limited partnership ("WP XII-E"), 24,903 shares of Common Stock sold by WP XII Partners, L.P., a Delaware limited partnership ("WP XII Partners"), 48,171 shares of Common Stock sold by Warburg Pincus XII Partners, L.P., a Delaware limited partnership ("Warburg Pincus XII Partners") pursuant the partial exercise by the underwriters of their over-allotment option (the "Transaction") after the closing of Alignment Healthcare Inc.'s initial public offering, at a price of $16.83 (net of underwriting discount).

F2 · ownership.nature: Reflects securities held directly by WP XII, WP XII-B, WP XII-D, WP XII-E, WP XII Partners, and Warburg Pincus XII Partners (together with WP XII, WP XII-B, WP XII-D, WP XII-E, and WP XII Partners, the "WP XII Funds") following the closing of the Transaction. Warburg Pincus XII, L.P., a Delaware limited partnership ("WP XII GP"), is the general partner of the WP XII Funds. WP Global LLC, a Delaware limited liability company ("WP Global"), is the general partner of WP XII GP. Warburg Pincus Partners II, L.P., a Delaware limited partnership ("WPP II"), is the managing member of WP Global. Warburg Pincus Partners GP LLC, a Delaware limited liability company ("WPP GP"), is the general partner of WPP II.

F3 · ownership.nature: (Continued Form Footnote 2 ) Warburg Pincus & Co., a New York general partnership ("WP"), is the managing member of WPP GP. Warburg Pincus LLC, a New York limited liability company ("WP LLC") is a registered investment adviser and the manager of the WP XII Funds. Investment and voting decisions with respect to the shares held by the WP XII Funds are made by a committee comprised of three or more individuals and all members of such committee disclaim beneficial ownership of the shares.

SEC source: 0000899243-21-015438 · doc4.xml · nonDerivative · entry 2

MARGOLIS JEFFREY H · CIK 0001105688 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 462,466

F3 · kind: Represents 10,121 shares of Common Stock sold pursuant to the partial exercise by the underwriters of their over-allotment option after the closing of the Company's initial public offering, at a price of $16.83 (net of underwriting discount).

F2 · ownership.nature: Represents securities held by the Margolis Family trust 12/23/98, of which Mr. Margolis is the trustee.

SEC source: 0000899243-21-015440 · doc4.xml · nonDerivative · entry 1

GENERAL ATLANTIC LLC · CIK 0001017645 · Director · 10% owner

General Atlantic (ALN HLTH), L.P. · CIK 0001853603 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 76,328,615

F1 · kind: The shares of Common Stock were sold by General Atlantic (ALN HLTH), L.P., a Delaware limited partnership ("GA ALN"), pursuant to the partial exercise by the underwriters of their over-allotment option (the "Transaction") after the closing of Alignment Healthcare, Inc.'s initial public offering, at a price of $16.83 (net of underwriting discount).

F2 · ownership.nature: Reflects securities held directly by GA ALN following the closing of the Transaction. The limited partners of GA ALN are the following investment funds (the "GA Funds"): General Atlantic Partners 95, L.P., a Delaware limited partnership ("GAP 95"), GAP Coinvestments CDA, L.P., a Delaware limited partnership ("GAPCO CDA"), GAP Coinvestments III, LLC, a Delaware limited liability company ("GAPCO III"), GAP Coinvestments IV, LLC, a Delaware limited liability company ("GAPCO IV"), GAP Coinvestments V, LLC, a Delaware limited liability company ("GAPCO V") and GAPCO GmbH & Co. KG, a German partnership ("GAPCO KG"). General Atlantic GenPar, L.P., a Delaware limited partnership ("GA GenPar"), is the general partner of GAP 95.

F3 · ownership.nature: (Continued From Footnote 2 ) General Atlantic (SPV) GP, LLC, a Delaware limited liability company ("GA SPV"), is the general partner of GA ALN. General Atlantic LLC, a Delaware limited liability company ("GA LLC") is the general partner of GA GenPar and GAPCO CDA, the managing member of GAPCO III, GAPCO IV and GAPCO V, and the sole member of GA SPV. GAPCO Management GmbH, a German company ("GAPCO Management"), is the general partner of GAPCO KG. There are nine members of the management committee of GA LLC (the "GA Management Committee"). Each of the members of the GA Management Committee disclaims ownership of the shares except to the extent he has a pecuniary interest therein.

SEC source: 0000899243-21-015436 · doc4.xml · nonDerivative · entry 1

GENERAL ATLANTIC LLC · CIK 0001017645 · Director · 10% owner

GAPCO GMBH & CO KG · CIK 0001187388 · Director · 10% owner

GAPCO MANAGEMENT GMBH · CIK 0001187390 · Director · 10% owner

GENERAL ATLANTIC GENPAR, L.P. · CIK 0001467926 · Director · 10% owner

General Atlantic Partners 95, L.P. · CIK 0001606259 · Director · 10% owner

GAP COINVESTMENTS III, LLC · CIK 0001282203 · Director · 10% owner

GAP COINVESTMENTS IV, LLC · CIK 0001282372 · Director · 10% owner

GAP Coinvestments V, LLC · CIK 0001793941 · Director · 10% owner

GAP Coinvestments CDA, L.P. · CIK 0001356474 · Director · 10% owner

General Atlantic (SPV) GP, LLC · CIK 0001793940 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 76,328,615

F1 · kind: The shares of Common Stock were sold by General Atlantic (ALN HLTH), L.P., a Delaware limited partnership ("GA ALN"), pursuant to the partial exercise by the underwriters of their over-allotment option (the "Transaction") after the closing of Alignment Healthcare, Inc.'s initial public offering, at a price of $16.83 (net of underwriting discount).

F2 · ownership.nature: Reflects securities held directly by GA ALN following the closing of the Transaction. The limited partners of GA ALN are the following investment funds (the "GA Funds"): General Atlantic Partners 95, L.P., a Delaware limited partnership ("GAP 95"), GAP Coinvestments CDA, L.P., a Delaware limited partnership ("GAPCO CDA"), GAP Coinvestments III, LLC, a Delaware limited liability company ("GAPCO III"), GAP Coinvestments IV, LLC, a Delaware limited liability company ("GAPCO IV"), GAP Coinvestments V, LLC, a Delaware limited liability company ("GAPCO V") and GAPCO GmbH & Co. KG, a German partnership ("GAPCO KG"). General Atlantic GenPar, L.P., a Delaware limited partnership ("GA GenPar"), is the general partner of GAP 95.

F3 · ownership.nature: (Continued From Footnote 2 ) General Atlantic (SPV) GP, LLC, a Delaware limited liability company ("GA SPV"), is the general partner of GA ALN. General Atlantic LLC, a Delaware limited liability company ("GA LLC") is the general partner of GA GenPar and GAPCO CDA, the managing member of GAPCO III, GAPCO IV and GAPCO V, and the sole member of GA SPV. GAPCO Management GmbH, a German company ("GAPCO Management"), is the general partner of GAPCO KG. There are nine members of the management committee of GA LLC (the "GA Management Committee"). Each of the members of the GA Management Committee disclaims ownership of the shares except to the extent he has a pecuniary interest therein.

SEC source: 0000899243-21-015451 · doc4.xml · nonDerivative · entry 1

WARBURG PINCUS LLC · CIK 0001162870 · Director · 10% owner

Warburg Pincus Private Equity XII, L.P. · CIK 0001658396 · Director · 10% owner

Warburg Pincus Private Equity XII-B, L.P. · CIK 0001658398 · Director · 10% owner

Warburg Pincus Private Equity XII-D, L.P. · CIK 0001658400 · Director · 10% owner

Warburg Pincus Private Equity XII-E, L.P. · CIK 0001658404 · Director · 10% owner

WP XII Partners, L.P. · CIK 0001658414 · Director · 10% owner

Warburg Pincus XII Partners, L.P. · CIK 0001658412 · Director · 10% owner

WARBURG PINCUS XII, L.P. · CIK 0001672765 · Director · 10% owner

WP Global LLC · CIK 0001540385 · Director · 10% owner

Warburg Pincus Partners II, L.P. · CIK 0001658787 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 24,802,721

F1 · kind: Represents 461,584 shares of Common Stock sold by Warburg Pincus Private Equity XII, L.P., a Delaware limited partnership ("WP XII"), 92,610 shares of Common Stock sold by Warburg Pincus Private Equity XII-B, L.P., a Delaware limited partnership ("WP XII-B"), 13,322 shares of Common Stock sold by Warburg Pincus Private Equity XII-D, L.P., a Delaware limited partnership ("WP XII-D"), and 76,034 share of Common Stock sold by Warburg Pincus Private Equity XII-E, L.P., a Delaware limited partnership ("WP XII-E"), 24,903 shares of Common Stock sold by WP XII Partners, L.P., a Delaware limited partnership ("WP XII Partners"), 48,171 shares of Common Stock sold by Warburg Pincus XII Partners, L.P., a Delaware limited partnership ("Warburg Pincus XII Partners") pursuant the partial exercise by the underwriters of their over-allotment option (the "Transaction") after the closing of Alignment Healthcare Inc.'s initial public offering, at a price of $16.83 (net of underwriting discount).

F2 · ownership.nature: Reflects securities held directly by WP XII, WP XII-B, WP XII-D, WP XII-E, WP XII Partners, and Warburg Pincus XII Partners (together with WP XII, WP XII-B, WP XII-D, WP XII-E, and WP XII Partners, the "WP XII Funds") following the closing of the Transaction. Warburg Pincus XII, L.P., a Delaware limited partnership ("WP XII GP"), is the general partner of the WP XII Funds. WP Global LLC, a Delaware limited liability company ("WP Global"), is the general partner of WP XII GP. Warburg Pincus Partners II, L.P., a Delaware limited partnership ("WPP II"), is the managing member of WP Global. Warburg Pincus Partners GP LLC, a Delaware limited liability company ("WPP GP"), is the general partner of WPP II.

F3 · ownership.nature: (Continued Form Footnote 2 ) Warburg Pincus & Co., a New York general partnership ("WP"), is the managing member of WPP GP. Warburg Pincus LLC, a New York limited liability company ("WP LLC") is a registered investment adviser and the manager of the WP XII Funds. Investment and voting decisions with respect to the shares held by the WP XII Funds are made by a committee comprised of three or more individuals and all members of such committee disclaim beneficial ownership of the shares.

SEC source: 0000899243-21-015443 · doc4.xml · nonDerivative · entry 2

Maroney Dawn Christine · CIK 0001850397 · President, Markets

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,641,776

F2 · kind: Represents 50,843 shares of Common Stock sold pursuant to the partial exercise by the underwriters of their over-allotment option after the closing of the Company's initial public offering, at a price of $16,83 (net of underwriting discount).

SEC source: 0000899243-21-015447 · doc4.xml · nonDerivative · entry 2

Foster Michael Curtis · CIK 0001850411 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,081,849

F2 · kind: Represents 50,843 shares of Common Stock sold pursuant to the partial exercise by the underwriters of their over-allotment option after the closing of the Company's initial public offering, at a price of $16.83 (net of underwriting discount).

SEC source: 0000899243-21-015446 · doc4.xml · nonDerivative · entry 4

Freeman Robert Thomas · CIK 0001850414 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 885,645

F6 · kind: Represents 38,919 shares of Common Stock sold pursuant to the partial exercise by the underwriters of their over-allotment option after the closing of the Company's initial public offering, at a price of $16.83 (net of underwriting discount).

F5 · ownership.nature: Represents securities held by FCO Holdings LLC, a limited liability company owned by FCO Holdings Trust One, an irrevocable trust of which Mr. Freeman is an indirect beneficiary.

SEC source: 0000899243-21-015437 · doc4.xml · nonDerivative · entry 2

McClellan Mark B. · CIK 0001567006 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 284,319

F2 · kind: Represents 12,103 shares of Common Stock sold pursuant to the partial exercise by the underwriters of their over-allotment option after the closing of the Company's initial public offering, at a price of $16.83 (net of underwriting discount).

SEC source: 0000950142-21-001592 · es210148620_4a-freeman.xml · nonDerivative · entry 3

Freeman Robert Thomas · CIK 0001850414 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 840,218

F4 · kind: Represents 38,919 shares of Common Stock sold pursuant to the partial exercise by the underwriters of their over-allotment option after the closing of the Company's initial public offering, at a price of $16.83 (net of underwriting discount).

F5 · ownership.nature: Represents securities held by FCO Holdings LLC, a limited liability company owned by FCO Holdings Trust One, an irrevocable trust of which Mr. Freeman is an indirect beneficiary.

SEC source: 0000899243-21-014418 · doc4.xml · nonDerivative · entry 1

WARBURG PINCUS LLC · CIK 0001162870 · Director · 10% owner

Warburg Pincus Partners GP LLC · CIK 0001621224 · Director · 10% owner

WARBURG PINCUS & CO. · CIK 0000929408 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 25,519,345

F1 · kind: Represents 806,213 shares of Common Stock sold by Warburg Pincus Private Equity XII, L.P., a Delaware limited partnership ("WP XII"), 161,753 shares of Common Stock sold by Warburg Pincus Private Equity XII-B, L.P., a Delaware limited partnership ("WP XII-B"), 23,269 shares of Common Stock sold by Warburg Pincus Private Equity XII-D, L.P., a Delaware limited partnership ("WP XII-D"), and 132,802 share of Common Stock sold by Warburg Pincus Private Equity XII-E, L.P., a Delaware limited partnership ("WP XII-E"), 43,496 shares of Common Stock sold by WP XII Partners, L.P., a Delaware limited partnership ("WP XII Partners"), 84,137 shares of Common Stock sold by Warburg Pincus XII Partners, L.P., a Delaware limited partnership ("Warburg Pincus XII Partners") in the initial public offering of Alignment Healthcare, Inc. which closed on March 30, 2021 (the "Offering"), at a price of $16.83 (net of underwriting discount).

F2 · ownership.nature: Reflects securities held directly by WP XII, WP XII-B, WP XII-D, WP XII-E, WP XII Partners, and Warburg Pincus XII Partners (together with WP XII, WP XII-B, WP XII-D, WP XII-E, and WP XII Partners, the "WP XII Funds") following the closing of the Offering. Warburg Pincus XII, L.P., a Delaware limited partnership ("WP XII GP"), is the general partner of the WP XII Funds. WP Global LLC, a Delaware limited liability company ("WP Global"), is the general partner of WP XII GP. Warburg Pincus Partners II, L.P., a Delaware limited partnership ("WPP II"), is the managing member of WP Global. Warburg Pincus Partners GP LLC, a Delaware limited liability company ("WPP GP"), is the general partner of WPP II. Warburg Pincus & Co., a New York general partnership ("WP"), is the managing member of WPP GP. Warburg Pincus LLC, a New York limited liability company ("WP LLC") is a registered investment adviser and the manager of the WP XII Funds.

F3 · ownership.nature: (Continued from footnote 2) Investment and voting decisions with respect to the shares held by the WP XII Funds are made by a committee comprised of three or more individuals and all members of such committee disclaim beneficial ownership of the shares.

SEC source: 0000899243-21-014417 · doc4.xml · nonDerivative · entry 1

GENERAL ATLANTIC LLC · CIK 0001017645 · Director · 10% owner

General Atlantic (ALN HLTH), L.P. · CIK 0001853603 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 78,511,411

F1 · kind: The shares of Common Stock were sold by General Atlantic (ALN HLTH), L.P., a Delaware limited partnership ("GA ALN"), in the initial public offering of Alignment Healthcare, Inc. which closed on March 30, 2021 (the "Offering"), at a price of $16.83 (net of underwriting discount).

F2 · ownership.nature: Reflects securities held directly by GA ALN following the closing of the Offering. The limited partners of GA ALN are the following investment funds (the "GA Funds"): General Atlantic Partners 95, L.P., a Delaware limited partnership ("GAP 95"), GAP Coinvestments CDA, L.P., a Delaware limited partnership ("GAPCO CDA"), GAP Coinvestments III, LLC, a Delaware limited liability company ("GAPCO III"), GAP Coinvestments IV, LLC, a Delaware limited liability company ("GAPCO IV"), GAP Coinvestments V, LLC, a Delaware limited liability company ("GAPCO V") and GAPCO GmbH & Co. KG, a German partnership ("GAPCO KG"). General Atlantic GenPar, L.P., a Delaware limited partnership ("GA GenPar"), is the general partner of GAP 95. General Atlantic (SPV) GP, LLC, a Delaware limited liability company ("GA SPV"), is the general partner of GA ALN.

F3 · ownership.nature: (Continued from footnote 2) General Atlantic LLC, a Delaware limited liability company ("GA LLC") is the general partner of GA GenPar and GAPCO CDA, the managing member of GAPCO III, GAPCO IV and GAPCO V, and the sole member of GA SPV. GAPCO Management GmbH, a German company ("GAPCO Management"), is the general partner of GAPCO KG. There are nine members of the management committee of GA LLC (the "GA Management Committee"). Each of the members of the GA Management Committee disclaims ownership of the shares except to the extent he has a pecuniary interest therein.

SEC source: 0000899243-21-014409 · doc4.xml · nonDerivative · entry 1

GENERAL ATLANTIC LLC · CIK 0001017645 · Director · 10% owner

GAPCO GMBH & CO KG · CIK 0001187388 · Director · 10% owner

GAPCO MANAGEMENT GMBH · CIK 0001187390 · Director · 10% owner

GENERAL ATLANTIC GENPAR, L.P. · CIK 0001467926 · Director · 10% owner

General Atlantic Partners 95, L.P. · CIK 0001606259 · Director · 10% owner

GAP COINVESTMENTS III, LLC · CIK 0001282203 · Director · 10% owner

GAP COINVESTMENTS IV, LLC · CIK 0001282372 · Director · 10% owner

GAP Coinvestments V, LLC · CIK 0001793941 · Director · 10% owner

GAP Coinvestments CDA, L.P. · CIK 0001356474 · Director · 10% owner

General Atlantic (SPV) GP, LLC · CIK 0001793940 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 78,511,411

F1 · kind: The shares of Common Stock were sold by General Atlantic (ALN HLTH), L.P., a Delaware limited partnership ("GA ALN"), in the initial public offering of Alignment Healthcare, Inc. which closed on March 30, 2021 (the "Offering"), at a price of $16.83 (net of underwriting discount).

F2 · ownership.nature: Reflects securities held directly by GA ALN following the closing of the Offering. The limited partners of GA ALN are the following investment funds (the "GA Funds"): General Atlantic Partners 95, L.P., a Delaware limited partnership ("GAP 95"), GAP Coinvestments CDA, L.P., a Delaware limited partnership ("GAPCO CDA"), GAP Coinvestments III, LLC, a Delaware limited liability company ("GAPCO III"), GAP Coinvestments IV, LLC, a Delaware limited liability company ("GAPCO IV"), GAP Coinvestments V, LLC, a Delaware limited liability company ("GAPCO V") and GAPCO GmbH & Co. KG, a German partnership ("GAPCO KG"). General Atlantic GenPar, L.P., a Delaware limited partnership ("GA GenPar"), is the general partner of GAP 95. General Atlantic (SPV) GP, LLC, a Delaware limited liability company ("GA SPV"), is the general partner of GA ALN.

F3 · ownership.nature: (Continued from footnote 2) General Atlantic LLC, a Delaware limited liability company ("GA LLC") is the general partner of GA GenPar and GAPCO CDA, the managing member of GAPCO III, GAPCO IV and GAPCO V, and the sole member of GA SPV. GAPCO Management GmbH, a German company ("GAPCO Management"), is the general partner of GAPCO KG. There are nine members of the management committee of GA LLC (the "GA Management Committee"). Each of the members of the GA Management Committee disclaims ownership of the shares except to the extent he has a pecuniary interest therein.

SEC source: 0000899243-21-014415 · doc4.xml · nonDerivative · entry 1

WARBURG PINCUS LLC · CIK 0001162870 · Director · 10% owner

Warburg Pincus Private Equity XII, L.P. · CIK 0001658396 · Director · 10% owner

Warburg Pincus Private Equity XII-B, L.P. · CIK 0001658398 · Director · 10% owner

Warburg Pincus Private Equity XII-D, L.P. · CIK 0001658400 · Director · 10% owner

Warburg Pincus Private Equity XII-E, L.P. · CIK 0001658404 · Director · 10% owner

WP XII Partners, L.P. · CIK 0001658414 · Director · 10% owner

Warburg Pincus XII Partners, L.P. · CIK 0001658412 · Director · 10% owner

WARBURG PINCUS XII, L.P. · CIK 0001672765 · Director · 10% owner

WP Global LLC · CIK 0001540385 · Director · 10% owner

Warburg Pincus Partners II, L.P. · CIK 0001658787 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 25,519,345

F1 · kind: Represents 806,213 shares of Common Stock sold by Warburg Pincus Private Equity XII, L.P., a Delaware limited partnership ("WP XII"), 161,753 shares of Common Stock sold by Warburg Pincus Private Equity XII-B, L.P., a Delaware limited partnership ("WP XII-B"), 23,269 shares of Common Stock sold by Warburg Pincus Private Equity XII-D, L.P., a Delaware limited partnership ("WP XII-D"), and 132,802 share of Common Stock sold by Warburg Pincus Private Equity XII-E, L.P., a Delaware limited partnership ("WP XII-E"), 43,496 shares of Common Stock sold by WP XII Partners, L.P., a Delaware limited partnership ("WP XII Partners"), 84,137 shares of Common Stock sold by Warburg Pincus XII Partners, L.P., a Delaware limited partnership ("Warburg Pincus XII Partners") in the initial public offering of Alignment Healthcare, Inc. which closed on March 30, 2021 (the "Offering"), at a price of $16.83 (net of underwriting discount).

F2 · ownership.nature: Reflects securities held directly by WP XII, WP XII-B, WP XII-D, WP XII-E, WP XII Partners, and Warburg Pincus XII Partners (together with WP XII, WP XII-B, WP XII-D, WP XII-E, and WP XII Partners, the "WP XII Funds") following the closing of the Offering. Warburg Pincus XII, L.P., a Delaware limited partnership ("WP XII GP"), is the general partner of the WP XII Funds. WP Global LLC, a Delaware limited liability company ("WP Global"), is the general partner of WP XII GP. Warburg Pincus Partners II, L.P., a Delaware limited partnership ("WPP II"), is the managing member of WP Global. Warburg Pincus Partners GP LLC, a Delaware limited liability company ("WPP GP"), is the general partner of WPP II. Warburg Pincus & Co., a New York general partnership ("WP"), is the managing member of WPP GP. Warburg Pincus LLC, a New York limited liability company ("WP LLC") is a registered investment adviser and the manager of the WP XII Funds.

F3 · ownership.nature: (Continued from footnote 2) Investment and voting decisions with respect to the shares held by the WP XII Funds are made by a committee comprised of three or more individuals and all members of such committee disclaim beneficial ownership of the shares.

SEC source: 0000899243-21-014410 · doc4.xml · nonDerivative · entry 2

McCarthy Margaret M · CIK 0001485980 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,333

F2 · kind: Represents 10,000 shares of Common Stock of the Company purchased through a directed share program at the initial offering price of the Common Stock.

SEC source: 0000899243-21-014408 · doc4.xml · nonDerivative · entry 3

KOSECOFF JACQUELINE B · CIK 0001209524 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,640

F3 · kind: Represents 10,000 shares of Common Stock purchased through a directed share program at the initial offering price of the Common Stock.

SEC source: 0000899243-21-015550 · doc4a.xml · nonDerivative · entry 3

KOSECOFF JACQUELINE B · CIK 0001209524 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 192,983

F3 · kind: Represents 10,000 shares of Common Stock purchased through a directed share program at the initial offering price of the Common Stock.

SEC source: 0000899243-21-014410 · doc4.xml · nonDerivative · entry 1

McCarthy Margaret M · CIK 0001485980 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,333

F1 · kind: Represents 33,333 shares of restricted Common Stock of Alignment Healthcare, Inc. (the "Company") that will vest in equal annual installments on each of the first three anniversaries of the Company's initial public offering unless Ms. McCarthy is removed for cause or resigns prior to such dates. The securities covered by such transaction were previously included on Ms. McCarthy's Form 3.

SEC source: 0000899243-21-014408 · doc4.xml · nonDerivative · entry 2

KOSECOFF JACQUELINE B · CIK 0001209524 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,460

F2 · kind: Represents 33,333 shares of restricted Common Stock of the Company that will vest in equal annual installments on each of the first three anniversaries of the IPO unless Ms. Kosecoff is removed for cause or resigns prior to such dates. The securities covered by such transaction were previously included on Ms. Kosecoff's Form 3.

SEC source: 0000899243-21-014408 · doc4.xml · nonDerivative · entry 1

KOSECOFF JACQUELINE B · CIK 0001209524 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,127

F1 · kind: Represents 11,418 shares of Common Stock of Alignment Healthcare, Inc. (the "Company") and 5,709 restricted shares of Common Stock of the Company that will vest upon a change of control of the Company or otherwise (A) if received in exchange for pre-IPO (as defined below) transaction-based stock appreciation rights, on the later of (x) the four-year anniversary of the initial vesting date, or (y) 50% on the first anniversary of Company's initial public offering (the "IPO") and 50% on the second anniversary of the IPO, in each case, subject to Ms. Kosecoff's continued employment or service on each such vesting date and (B) if received in exchange for pre-IPO service-based stock appreciation rights, according to the pre-IPO vesting schedule of the pre-IPO service-based stock appreciation rights. The securities covered by such transaction were previously included on Ms. Kosecoff's Form 3.

SEC source: 0000899243-21-015438 · doc4.xml · nonDerivative · entry 1

MARGOLIS JEFFREY H · CIK 0001105688 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 472,587

F1 · kind: Represents 33,333 shares of restricted Common Stock of Alignment Healthcare, Inc. (the "Company") that will vest in equal annual installments on each of the first three anniversaries of the Company's initial public offering unless Mr. Margolis is removed for cause or resigns prior to such dates. The securities covered by such transaction were previously included on Mr. Margolis's Form 3.

F2 · ownership.nature: Represents securities held by the Margolis Family trust 12/23/98, of which Mr. Margolis is the trustee.

SEC source: 0000899243-21-015443 · doc4.xml · derivative · entry 3

Maroney Dawn Christine · CIK 0001850397 · President, Markets

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 346,296

Underlying: Common Stock · 1,030,702 shares

Expires 2031-03-25

F3 · kind: Represents 1,030,702 options to purchase Common Stock of the Company at the initial public offering price. The securities covered by such transaction were previously included on Ms. Maroney's Form 3.

F4 · derivative.exercise_date: Vest 25% on the first four anniversaries of the initial vesting date.

SEC source: 0000899243-21-015443 · doc4.xml · nonDerivative · entry 1

Maroney Dawn Christine · CIK 0001850397 · President, Markets

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,716,998

F1 · kind: Represents 81,850 restricted stock units, each restricted stock unit representing the right to receive one share of Common Stock of Alignment Healthcare, Inc. (the "Company"), that will vest 25% on the first four anniversaries of the initial vesting date. The securities covered by such transaction were previously included on Ms. Maroney's Form 3.